AJP - Cell Physiology, Vol 265, Issue 1 C188-C192, Copyright © 1993 by American Physiological Society

ARTICLES

Downregulation of endothelin receptors by autocrine production of endothelin-1

M. Clozel, B. M. Loffler, V. Breu, L. Hilfiger, J. P. Maire and B. Butscha
Pharma Division, Preclinical Research, F. Hoffmann-La Roche Ltd., Basel, Switzerland.

The potent vasoconstrictor endothelin-1 (ET-1) is a paracrine, but also autocrine, factor for some types of cells. The goal of our study was to evaluate whether the receptor population in cells expressing endothelin receptor subtype A (rat mesangial cells) or endothelin receptor subtype B (human and rat endothelial cells) was affected by the autocrine production of ET-1. We therefore studied maximal binding capacity of 125I-labeled ET-1 in the presence or absence of the metalloprotease inhibitors phosphoramidon, which blocks the intracellular processing of Big ET-1 to ET-1, and thiorphan, which does not block this conversion. Phosphoramidon inhibited the release of ET-1 by human umbilical vein endothelial cells, rat aortic endothelial cells, and rat mesangial cells, and increased 1.4- to 17-fold the maximal binding capacity in the three types of cells. Thiorphan affected neither ET-1 release nor binding. The increase in receptor binding by phosphoramidon was associated with an increase in the functional effect of ET-1, as measured by arachidonic acid release in rat mesangial cells. We conclude that autocrine production of ET-1 decreases, either by binding or by downregulation, the number of binding sites available for ET-1 of paracrine or systemic sources. This aspect of modulation of the vasoconstrictor effect of endothelin should be considered in pathological situations or after endothelin-converting-enzyme inhibition.

This article has been cited by other articles:

				L. L. Yanes, D. G. Romero, V. E. Cucchiarelli, L. A. Fortepiani, C. E. Gomez-Sanchez, F. Santacruz, and J. F. Reckelhoff Role of endothelin in mediating postmenopausal hypertension in a rat model Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2005; 288(1): R229 - R233. [Abstract] [Full Text] [PDF]

				S. Motte, R. van Beneden, J. Mottet, B. Rondelet, M. Mathieu, X. Havaux, P. Lause, C. Clercx, J.-M. Ketelslegers, R. Naeije, et al. Early activation of cardiac and renal endothelin systems in experimental heart failure Am J Physiol Heart Circ Physiol, December 1, 2003; 285(6): H2482 - H2491. [Abstract] [Full Text] [PDF]

				B. Ovadia, O. Reinhartz, R. Fitzgerald, J. M. Bekker, M. J. Johengen, A. Azakie, S. Thelitz, S. M. Black, and J. R. Fineman Alterations in ET-1, not nitric oxide, in 1-week-old lambs with increased pulmonary blood flow Am J Physiol Heart Circ Physiol, February 1, 2003; 284(2): H480 - H490. [Abstract] [Full Text] [PDF]

				O. Zolk, J. Quattek, G. Sitzler, T. Schrader, G. Nickenig, P. Schnabel, K. Shimada, M. Takahashi, and M. Bohm Expression of Endothelin-1, Endothelin-Converting Enzyme, and Endothelin Receptors in Chronic Heart Failure Circulation, April 27, 1999; 99(16): 2118 - 2123. [Abstract] [Full Text] [PDF]